Online Trial Tracker - Larvol Sigma

Welcome, Profile Billing Logout

1 Trials

All TrialsIndustry lead sponsorIndustry collaboratorPhase 2

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

imatinib / Generic mfg.

NCT00154388: Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Completed

185

US, Europe, RoW

Imatinib mesylate

Novartis Pharmaceuticals

Life Threatening Diseases

01/07

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites